RxDoctor Payments Data

Larry Levine, DO

General Practice · Dunedin, FLNPI 1811991540

Payments from drug & device makers

$256in general payments, 2019–2025

Across 8 payments — averaging $31.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardinal Health 200 LLC$114
  • Sunovion Pharmaceuticals Inc.$41
  • Cipher Pharmaceuticals US LLC$34
  • Lilly USA, LLC$24
  • Boston Scientific$23
  • UCB, Inc.$19

What the payments were for

  • Food & beverage$256100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cardinal Health 200 LLC2$114
Sunovion Pharmaceuticals Inc.2$41
Cipher Pharmaceuticals US LLC1$34
Lilly USA, LLC1$24
Boston Scientific1$23
UCB, Inc.1$19

How this compares

$256 in reported general payments places this provider in the 45th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$210,120
Medicare patients
447
Services billed
2,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban879$262,930
AustedoDeutetrabenazine60$157,599
NuplazidPimavanserin Tartrate33$81,723
Divalproex Sodium550$49,689
LinzessLinaclotide85$49,474
XifaxanRifaximin33$48,735
TrulicityDulaglutide76$46,250
BiktarvyBictegrav/Emtricit/Tenofov Ala11$45,353
TivicayDolutegravir Sodium27$43,675
JardianceEmpagliflozin134$42,915
SantylCollagenase Clostridium Hist.12$36,158
NuedextaDextromethorphan Hbr/Quinidine48$35,520
JanuviaSitagliptin Phosphate111$33,211
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$32,262
AptiomEslicarbazepine Acetate38$24,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$24$46,25076 claims
Sunovion Pharmaceuticals Inc.Aptiom$41$24,03638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 6,901 general practice providers in Florida.

Other general practice in Dunedin

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →